These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 24453002)

  • 1. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
    Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA
    Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
    Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
    Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
    [No Abstract]   [Full Text] [Related]  

  • 3. PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
    Sachamitr P; Ho JC; Ciamponi FE; Ba-Alawi W; Coutinho FJ; Guilhamon P; Kushida MM; Cavalli FMG; Lee L; Rastegar N; Vu V; Sánchez-Osuna M; Coulombe-Huntington J; Kanshin E; Whetstone H; Durand M; Thibault P; Hart K; Mangos M; Veyhl J; Chen W; Tran N; Duong BC; Aman AM; Che X; Lan X; Whitley O; Zaslaver O; Barsyte-Lovejoy D; Richards LM; Restall I; Caudy A; Röst HL; Bonday ZQ; Bernstein M; Das S; Cusimano MD; Spears J; Bader GD; Pugh TJ; Tyers M; Lupien M; Haibe-Kains B; Artee Luchman H; Weiss S; Massirer KB; Prinos P; Arrowsmith CH; Dirks PB
    Nat Commun; 2021 Feb; 12(1):979. PubMed ID: 33579912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
    BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
    Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
    PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
    Otani Y; Sur HP; Rachaiah G; Namagiri S; Chowdhury A; Lewis CT; Shimizu T; Gangaplara A; Wang X; Vézina A; Maric D; Jackson S; Yan Y; Zhengping Z; Ray-Chaudhury A; Kumar S; Ballester LY; Chittiboina P; Yoo JY; Heiss J; Kaur B; Banasavadi-Siddegowda YK
    Neuro Oncol; 2021 Sep; 23(9):1481-1493. PubMed ID: 33556161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
    Xia T; Liu M; Zhao Q; Ouyang J; Xu P; Chen B
    Cell Death Dis; 2021 Sep; 12(10):851. PubMed ID: 34531375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
    Jiang Y; Yuan Y; Chen M; Li S; Bai J; Zhang Y; Sun Y; Wang G; Xu H; Wang Z; Zheng Y; Nie H
    Theranostics; 2021; 11(18):9162-9176. PubMed ID: 34522232
    [No Abstract]   [Full Text] [Related]  

  • 9. PRMT5 promotes colorectal cancer growth by interaction with MCM7.
    Li X; Wang X; Zhao J; Wang J; Wu J
    J Cell Mol Med; 2021 Apr; 25(7):3537-3547. PubMed ID: 33675123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth.
    Liu L; Yan H; Ruan M; Yang H; Wang L; Lei B; Sun X; Chang C; Huang G; Xie W
    Cancer Sci; 2021 Aug; 112(8):3083-3098. PubMed ID: 34033176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer.
    Hu R; Zhou B; Chen Z; Chen S; Chen N; Shen L; Xiao H; Zheng Y
    Front Immunol; 2021; 12():722188. PubMed ID: 35111150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation.
    Ge S; Zhang Q; Chen Y; Tian Y; Yang R; Chen X; Li F; Zhang B
    Toxicol Appl Pharmacol; 2021 Mar; 415():115450. PubMed ID: 33577917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype.
    Ezeka G; Adhikary G; Kandasamy S; Friedberg JS; Eckert RL
    Mol Carcinog; 2021 Jul; 60(7):429-439. PubMed ID: 33872411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein arginine methyltransferase 5 (PRMT5) activates WNT/β-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
    Shailesh H; Siveen KS; Sif S
    J Cell Mol Med; 2021 Feb; 25(3):1583-1600. PubMed ID: 33462997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
    Sloan SL; Brown F; Long M; Weigel C; Koirala S; Chung JH; Pray B; Villagomez L; Hinterschied C; Sircar A; Helmig-Mason J; Prouty A; Brooks E; Youssef Y; Hanel W; Parekh S; Chan WK; Chen Z; Lapalombella R; Sehgal L; Vaddi K; Scherle P; Chen-Kiang S; Di Liberto M; Elemento O; Meydan C; Foox J; Butler D; Mason CE; Baiocchi RA; Alinari L
    Blood; 2023 Sep; 142(10):887-902. PubMed ID: 37267517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
    Busacca S; Zhang Q; Sharkey A; Dawson AG; Moore DA; Waller DA; Nakas A; Jones C; Cain K; Luo JL; Salcedo A; Salaroglio IC; Riganti C; Le Quesne J; John T; Boutros PC; Zhang SD; Fennell DA
    Sci Rep; 2021 Apr; 11(1):7434. PubMed ID: 33795785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program.
    Huang M; Dong W; Xie R; Wu J; Su Q; Li W; Yao K; Chen Y; Zhou Q; Zhang Q; Li W; Cheng L; Peng S; Chen S; Huang J; Chen X; Lin T
    Cancer Commun (Lond); 2022 May; 42(5):447-470. PubMed ID: 35434944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies.
    Abumustafa W; Zamer BA; Khalil BA; Hamad M; Maghazachi AA; Muhammad JS
    Biomed Pharmacother; 2022 Jan; 145():112368. PubMed ID: 34794114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
    Bajbouj K; Ramakrishnan RK; Saber-Ayad M; Omar HA; Saheb Sharif-Askari N; Shafarin J; Elmoselhi AB; Ihmaid A; AlHaj Ali S; Alalool A; Abdullah R; Hamid Q
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms.
    Chen Y; Shao X; Zhao X; Ji Y; Liu X; Li P; Zhang M; Wang Q
    Biomed Pharmacother; 2021 Dec; 144():112252. PubMed ID: 34619493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.